CDK9-IN-41

CDK9-IN-41 is a potent CDK9, EGFR, HER2, and COX-2 kinases inhibitor with IC50s of 192.81 nM, 254.03 nM, 238.81 nM, and 775 nM. COX-2-IN-18 exhibits remarkable antitumor activity against leukemia cancer cells, colon cancer cells, melanoma cells, ovarian cells and breast cells[1].

Product Specifications

CAS Number

[1038061-96-9]

UNSPSC

12352005

Target

CDK; COX; EGFR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cox-2-in-18.html

Purity

98.84

Solubility

10 mM in DMSO

Smiles

O=S(C1=CC=C(CCN2C(SCC)=NC3=C(C=CC=C3)C2=O)C=C1)(N)=O

Molecular Formula

C18H19N3O3S2

Molecular Weight

389.49

References & Citations

[1] El-Azab AS, et al. Antitumor activity, multitarget mechanisms, and molecular docking studies of quinazoline derivatives based on a benzenesulfonamide scaffold: Cell cycle analysis. Bioorg Chem. 2020;104:104345.